THC Therapeutics Q3 FY24: revenue $0

Key figures from this report

These are the numbers THC Therapeutics reported for Q3 FY24, the quarter ended Apr 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$0Against $0 in Q3 FY2310-Q income statement, on EDGAR
2. Net income$105K+11% from $94K in Q3 FY2310-Q income statement, on EDGAR
3. Cash and cash equivalents$849+5560% from $15 in Q3 FY2310-Q balance sheet, on EDGAR
4. Cash from operations−$137KAgainst −$2K in Q3 FY2310-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters